Equities research analysts expect that Achillion Pharmaceuticals (NASDAQ:ACHN) will report earnings per share of ($0.14) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.13). Achillion Pharmaceuticals reported earnings of ($0.15) per share in the same quarter last year, which suggests a positive year over year growth rate of 6.7%. The business is scheduled to announce its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.56) to ($0.55). For the next financial year, analysts expect that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.62) to ($0.51). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter in the previous year, the company posted ($0.03) earnings per share.
Several hedge funds have recently made changes to their positions in the business. MetLife Investment Advisors LLC bought a new stake in shares of Achillion Pharmaceuticals in the 4th quarter worth approximately $162,000. TIAA CREF Investment Management LLC raised its holdings in shares of Achillion Pharmaceuticals by 13.2% in the 4th quarter. TIAA CREF Investment Management LLC now owns 363,571 shares of the biopharmaceutical company’s stock worth $1,047,000 after buying an additional 42,358 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Achillion Pharmaceuticals by 3.9% in the 4th quarter. Teachers Advisors LLC now owns 1,552,264 shares of the biopharmaceutical company’s stock worth $4,471,000 after buying an additional 57,782 shares in the last quarter. Sarissa Capital Management LP raised its holdings in shares of Achillion Pharmaceuticals by 17.0% in the 4th quarter. Sarissa Capital Management LP now owns 2,500,000 shares of the biopharmaceutical company’s stock worth $7,200,000 after buying an additional 363,200 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in shares of Achillion Pharmaceuticals in the 4th quarter worth approximately $2,880,000. Institutional investors own 82.10% of the company’s stock.
Shares of ACHN stock traded up $0.10 during mid-day trading on Wednesday, reaching $3.68. The stock had a trading volume of 766,675 shares, compared to its average volume of 1,901,607. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66. The company has a market capitalization of $502.17, a P/E ratio of -5.94 and a beta of 0.89.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Achillion Pharmaceuticals (ACHN) Will Post Earnings of -$0.14 Per Share” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/25/zacks-analysts-expect-achillion-pharmaceuticals-achn-will-post-earnings-of-0-14-per-share.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.